Industry News

Medical Product Stocks Q4 Earnings Roster: SYK, ISRG, RMD

2017-01-20 zacks
The fourth-quarter earnings season is in its nascent stage with 41 S&P 500 participants having reported results so far. According to our latest Earnings Trends report, the earnings cycle has seen an encouraging start, courtesy of stable bank results. The uptrend was the result of reduced regulatory burden, tax law changes and an improved outlook for the domestic economy. Per the latest Earnings Trends report, the fourth-quarter earnings for the S&P 500 companies are expected to be up 4.

Aduro (ADRO) Inks License Agreement with Stanford University

2017-01-20 zacks
Aduro Biotech, Inc. (ADRO - Free Report) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology. The company will leverage its proprietary live, attenuated double-deleted Listeria (LADD) immunotherapy platform to cater to personalized LADD-based cancer therapies (pLADD) and help encode a number of neoantigens identified through this technology.

Quest Diagnostics (DGX) Launches HBV Quantitative Test

2017-01-20 zacks
Quest Diagnostics Inc. (DGX - Free Report) , a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test. This helps physicians evaluate a patient's response to drug therapies for HBV infection. The test is first of its kind in the U.S. and will help effectively treat individuals infected with the virus.

San Diego's Cytori Scoops Up Azaya Therapeutics in Deal Worth $170 Million

2017-01-20 biospace
Proposed Acquisition of Azaya Therapeutics Assets Would Broaden Pipeline with Two Oncology Drugs for Large, Underserved Markets

Have Faith In Trump's Agenda - Cramer's Mad Money (1/19/17)

2017-01-20 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, January 19.

Novocure's Optune available at 500 U.S. cancer centers; shares ahead 10% premarket

2017-01-20 seekingalpha
Novocure (NASDAQ:NVCR) announces that doctors at 500 U.S. cancer centers have been certified to prescribe Optune to treat newly diagnosed and recurrent glioblastoma patients.

IRADIMED CORPORATION announces FY2017 and Q1 guidance; shares off 19%

2017-01-20 seekingalpha
For 2017, Company expects revenue of $23.9M -$24.3M, GAAP EPS of $0.07 - $0.08 and non-GAAP EPS of $0.14 - $0.18.

Amedica prices equity offering; shares down 32%

2017-01-20 seekingalpha
Penny stock Amedica (AMDA -32%) slumps on more than a 4x surge in volume in response to the pricing of its $4.5M public equity offering. The company is offering one share of common stock paired with 0.45 of a warrant to purchase one common share at $0.55 for a combined price of $0.51. Closing date is January 24.

Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

2017-01-20 zacks
Mallinckrodt plc (MNK - Free Report) , will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter’s investigation into the acquisition of Synacthen Depot by its Questcor division. Synacthen Depot, is a synthetic adrenocorticotropic hormone (ACTH) drug.

IBM And 3M Face Off In The Final Conference Championship Match

2017-01-19 seekingalpha
Who will win this battle of Dow titans that have been in the index since the 1970s?

Implantable Biomaterials Market Material, Application Analysis & Trends 2016-2025: $150+ Billion Growth Opportunities/Investment Opportunities - Research and Markets

2017-01-19 prnewswire
The Global Implantable Biomaterials Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $165.31 billion by 2025.

AbbVie And ANI Pharmaceuticals Appear Poised To Announce A Deal For LibiGel

2017-01-19 seekingalpha
In 2013, ANI Pharmaceuticals' CEO stated that he would look for a partner to take the lead and co-promote on LibiGel. AbbVie appears to be the partner.

NovoCure Release: Company???s Optune Now Available At 500 Cancer Treatment Centers In The U.S.

2017-01-19 devicespace
ST. HELIER, Jersey--(BUSINESS WIRE)--Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune® to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system. Physicians at an additional 291 medical institutions throughout the world also can prescribe Optune to GBM patients.

Baxter International Release: Company???s Renal Therapy Services Significantly Reduced Peritonitis Infections Among Home Dialysis Patients

2017-01-19 devicespace
DEERFIELD, Ill.--(BUSINESS WIRE)--Renal Therapy Services (RTS), a global provider of kidney care services that is owned by Baxter International Inc. (NYSE:BAX), announced that a continuous quality improvement program has reduced peritonitis by 65% over an eight-year period in 49 of its Renal Care Centers located in Colombia. The program is estimated to have prevented approximately 10,400 peritonitis episodes, saved approximately $200,000 per year, and helped achieve an infection rate that is significantly lower than the benchmark set by the International Society of Peritoneal Dialysis (ISPD).

InVivo Therapeutics Release: Company Announces New Patient Enrollment Into The INSPIRE Study

2017-01-19 devicespace
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). Travis Dumont, M.D., an INSPIRE Principal Investigator, performed the implantation on January 16, 2017, approximately 67 hours after the injury occurred.

Nexeon MedSystems Release: Company Announces Effectiveness Of Form 10 And Closing Of $4.3M

2017-01-19 devicespace
LEXINGTON, Ky., Jan. 19, 2017 /PRNewswire-iReach/ -- Nexeon MedSystems Inc. ("Nexeon" or "the Company") announced today that it has closed a round of private funding that included new and previous investors.  This round will allow the Company to expand manufacturing capacity to service additional customers and to begin building commercial product launch infrastructure in Europe. 

Bovie Medical Corporation Release: Company Announce Sales Channel Partnership With ConMed For PlazXact

2017-01-19 devicespace
CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical (NYSE MKT: BVX), announced that it has entered into a global sales channel partnership agreement with CONMED (NASDAQ: CNMD) for its PlazXact™ Ablator, which will be marketed as the UltrAblator Bipolar® series effective in March 2017.

Bovie Medical up 6% premarket on CONMED deal for PlazXact Ablator

2017-01-19 seekingalpha
Bovie Medical (NYSEMKT:BVX) is up 6% premarket on light volume in response to its announcement that it has inked a deal with CONMED (NASDAQ:CNMD) under which it will sell Bovie's PlazXact Ablator, marketed as the UltrAblator Bipolar, starting in March.

Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

2017-01-19 zacks
Bioblast Pharma Ltd. (ORPN - Free Report) announced positive results from a phase IIa study on its lead candidate, trehalose, for the treatment of patients with spinocerebellar ataxia type 3 (SCA3). A look at Bioblast’s price movement during the past one year shows that the company has underperformed the Medical Drugs industry. Specifically, the stock lost 57.9%, while the industry fell 11.2%.

Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

2017-01-19 zacks
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Can Glaukos (GKOS) Stock Continue to Grow Earnings?

2017-01-19 zacks
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

2017-01-19 zacks
Shares of Apricus Biosciences, Inc. (APRI - Free Report) surged almost 90% after the company announced that its topical cream Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction. However, a look at Apricus’ price movement in the past one year shows that the company has underperformed the Medical Drugs industry. Specifically, the stock lost 78.9%, while the industry fell 11.

Orthofix to pay $14M to settle charges of improper revenue recognition and paying bribes to Brazilian doctors

2017-01-19 seekingalpha
Reuters reports that Orthofix International NV (OFIX) has agreed to pay $14M to settle charges that it paid doctors in Brazil to boost sales and improperly booked revenue.

The Best Dividend Stocks for Long-Term Investors

2017-01-19 fool
Dividend stocks pay out cash to shareholders each year. The best dividend stocks for investors feature two traits: healthy income and future payout growth. Let's look at five of the best dividend stocks for long-term investors: AT&T (NYSE:T), ExxonMobil (NYSE:XOM), Johnson & Johnson (NYSE:JNJ), 3M (NYSE:MMM), and Procter & Gamble (NYSE:PG).

Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?

2017-01-19 zacks
Boston Scientific Corporation (BSX - Free Report) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2. Last quarter, the company’s earnings were in line with the Zacks Consensus Estimate. It posted an average beat of 5.17% in the trailing four quarters. Let’s see how things are shaping up prior to this announcement.